Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Burning Rock Biotech (BNR) EBIT: 2020-2025

Historic EBIT for Burning Rock Biotech (BNR) over the last 6 years, with Sep 2025 value amounting to -$2.3 million.

  • Burning Rock Biotech's EBIT rose 65.61% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.7 million, marking a year-over-year increase of 75.66%. This contributed to the annual value of -$49.0 million for FY2024, which is 48.04% up from last year.
  • Latest data reveals that Burning Rock Biotech reported EBIT of -$2.3 million as of Q3 2025, which was down 40.32% from -$1.6 million recorded in Q2 2025.
  • Burning Rock Biotech's 5-year EBIT high stood at -$1.6 million for Q2 2025, and its period low was -$41.5 million during Q1 2022.
  • Its 3-year average for EBIT is -$13.6 million, with a median of -$15.2 million in 2024.
  • As far as peak fluctuations go, Burning Rock Biotech's EBIT crashed by 59.81% in 2021, and later soared by 89.26% in 2025.
  • Over the past 5 years, Burning Rock Biotech's EBIT (MRQ) stood at -$40.5 million in 2021, then grew by 13.87% to -$34.9 million in 2022, then grew by 27.40% to -$25.3 million in 2023, then soared by 61.67% to -$9.7 million in 2024, then surged by 76.41% to -$2.3 million in 2025.
  • Its EBIT was -$2.3 million in Q3 2025, compared to -$1.6 million in Q2 2025 and -$2.1 million in Q1 2025.